SYK
50
4
LB
64
2
NEM
61
-2
IBM
54
4
MRK
50
2
PAYX
56
3
DAL
46
2
NAVI
36
4
NDAQ
67
4
BF.B
51
3
DOW
26
2
TGT
50
2
REGN
24
-6
LH
58
8
PYPL
39
4
ORLY
64
14
UNP
39
4
SCHW
64
3
LEG
57
22
VZ
55
5
SYK
50
4
LB
64
2
NEM
61
-2
IBM
54
4
MRK
50
2
PAYX
56
3
DAL
46
2
NAVI
36
4
NDAQ
67
4
BF.B
51
3
DOW
26
2
TGT
50
2
REGN
24
-6
LH
58
8
PYPL
39
4
ORLY
64
14
UNP
39
4
SCHW
64
3
LEG
57
22
VZ
55
5
Financhill
Back

Materialise NV 10K Form

Buy
63

MTLS
Materialise NV

Last Price:
$5.14
Seasonality Move:
9.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MTLS News And Ratings

See the #1 stock for the next 7 days that we like better than MTLS

MTLS Financial Statistics

Sales & Book Value

Annual Sales: $288.7M
Cash Flow: $8.3M
Price / Cash Flow: 51.02
Annual Sales: $4.56
Price / Book: 1.14

Profitability

EPS (TTM): 0.17310
Net Income (TTM): $10.4M
Gross Margin: $163.2M
Return on Equity: 3.92%
Return on Assets: 2.44%

Materialise NV Earnings Forecast

Key Materialise NV Financial Ratios

  • The Gross Profit Margin over the past 13 years for MTLS is 56.54%.
  • The Selling, General & Administrative Expenses for MTLS have been equal to 36.04% of Gross Profit Margin.
  • The Research & Development expenses have been 16.64% of Revenue.
  • The Interest Expense is 9.67% of Operating Income.
  • The Net Earning history of MTLS is 5.04% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 7 years.

Materialise NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Software
Sector: Information Technology
Current Symbol: MTLS
CUSIP: 57667T
Website: materialise.com

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 1.88
Quick Ratio: 1.56

Price-to-Earnings

Trailing P/E Ratio: 20.93
Forward P/E Ratio: 17.67

MTLS Technical Analysis vs Fundamental Analysis

Buy
63
Materialise NV (MTLS) is a Buy

Is Materialise NV a Buy or a Sell?

  • Materialise NV stock is rated a Buy
    The current Materialise NV [MTLS] share price is $5.21. The Score for MTLS is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.